Short answer
ANGIODYNAMICS INC (ANGO) filed its fiscal 2026 10-K annual report with the SEC on Jul 14, 2026. It reported revenue of $320M (+9.5% year over year) and net income of −$37M.
- Top risk flagged: Regulatory risk: FDA increased scrutiny on Quality System Regulation compliance and post-market requirements following July 2025 enactment of the One Big Beautiful Bill Act
FY2026 key financial metrics · XBRL
- Revenue
- $320M
- +9.5% YoY
- Net income
- −$37M
- −8.1% YoY
- Operating margin
- -12.5%
- +1.2 pp YoY
- Gross margin
- 54.6%
- +0.7 pp YoY
- EPS (diluted)
- −$0.88
- −6.0% YoY
- ROE
- -21.5%
- −2.9 pp YoY
- Operating cash flow
- $3M
- +130.5% YoY
Source: XBRL data from the ANGIODYNAMICS INC (ANGO) FY2026 10-K on SEC EDGAR. USD.
ANGIODYNAMICS INC FY2026 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: design, manufacture, and sale of innovative medical devices for cardiovascular disease and cancer treatment
- New product emphasis: expanded FDA clearance for NanoKnife System prostate tissue ablation in Dec 2024 and MDR CE mark in Feb 2026 for multiple tumor ablations
- Strategic shift: divestiture of dialysis, BioSentry (June 2023), and PICC/Midline businesses (Feb 2024); discontinuation of RadioFrequency Ablation and Syntrax lines
- Quantitative metric: workforce reduced to approximately 632 full-time employees as of May 31, 2026
- Noteworthy fact: ongoing regulatory challenges delaying FDA clearances amid increased testing requirements and expanded MDR compliance through 2027-2028
Management Discussion & Analysis
- Revenue $320.2M, up 9.5% YoY ($292.5M in FY 2025); Med Tech grew 18.4% ($150.0M) strongest, Med Device up 2.6% ($170.2M)
- Gross margin 54.6% vs 53.9% YoY; Med Tech margin 63.6% vs 62.0%, Med Device margin declined 46.7% vs 47.7%
- Net loss increased to $36.7M from $34.0M; loss per share widened to $0.88 from $0.83
- Operating cash flow positive $3.1M vs negative $10.1M prior year; capex $2.6M plus $3.4M on unit placements; $1.7M stock buybacks in FY 2025, none in FY 2026
- Management pursuing restructuring to save $15M annually by FY 2027; share repurchase authorization $15M with $13.3M remaining; key risks include inflation, tariffs, supply chain disruptions
Risk Factors
- Regulatory risk: FDA increased scrutiny on Quality System Regulation compliance and post-market requirements following July 2025 enactment of the One Big Beautiful Bill Act
- Geopolitical risk: $0.7M revenue exposed to Iran distributors amid U.S. sanctions and rising Middle East conflicts impacting global trade and tariffs
- Supply chain vulnerability: Transition of manufacturing to third-party sites in U.S., Costa Rica, Latvia, Italy, Israel, China by Q1 FY2027 with risk of disruptions and increased costs
- Competitive risk: Price competition intensified by growing purchasing power of GPOs and IDNs, risking contract losses and reduced profitability
- Financial risk: CEO transition planned by Nov 2026 poses leadership uncertainty potentially impacting operations and investor confidence
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.